动脉样硬化中的免疫调节和失硫症会影响疾病的进展和治疗
Wei Lu1, Zhidong Zhang1, Gang Qiao1
1Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou 451460, China.
Biomedicines
|April 29, 2025
概括
这项研究揭示了动脉样硬化中的二硫化,确定了Cathepsin C (CTSC) 作为一种治疗标,通过减少光滑肌肉细胞亡来稳定斑块. 一个新的风险评分有助于识别高风险患者.
科学领域:
- 心血管生物学 心血管生物学
- 分子病理学分子病理学
- 生物信息学是一种生物信息学.
背景情况:
- 动脉样硬化是一种复杂的血管疾病,分子机制不明.
- 细胞异质性,代谢失调和慢性炎症是其关键特征.
- 现有研究尚未完全阐明导致动脉样硬化进展的复杂途径.
研究的目的:
- 在动脉样硬化斑块中综合地绘制免疫细胞相互作用和细胞异质性,使用scRNA-seq.
- 研究光滑肌细胞 (SMC) 的作用,并确定动脉样硬化的主要生物标志物.
- 为高风险患者开发和验证诊断风险评分模型.
主要方法:
- 单细胞RNA测序 (scRNA-seq) 用于免疫细胞映射和SMC异质性分析.
- 伪实时轨迹分析以了解SMC激活路径.
- 综合生物信息学 (WGCNA,机器学习) 用于识别生物标志物 (CTSC,TGFBI,GMFG) 并开发风险评分模型.
- 在体外和体内实验,以评估CTSC的功能作用.
主要成果:
- SMCs是占主导地位的细胞类型,表现出高的二硫化密度和动态激活通路.
- 观察到巨细胞和SMC之间的细胞间通信,在斑块区域具有特定的信号.
- 综合CTSC,TGFBI和GMFG的诊断风险评分准确识别了高风险患者.
- 在实验室中,CTSC敲除增强了SMC存活率和减少了亡;在体内研究显示,减少了斑块负担.
结论:
- 不硫化症在动脉样硬化发展中起着重要作用.
- 通过抑制SMC亡和氧化损伤,CTSC是稳定斑块的潜在治疗标.
- 开发的风险评分模型是患者分层和精确治疗的宝贵工具.
相关概念视频
01:38Inflammation
51.8K
Overview
51.8K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
109
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
109
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
108
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
108
01:29Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
01:28Inflammatory Response
1.6K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
329
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329